Gilead Sciences has begun enrollment in a Phase II trial of its investigational integrase-based, single-tablet, once-daily regimen of elvitegravir, GS 9350 and Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for the treatment of HIV-1 infection. GS 9350 is being developed as a pharmacoenhancing or “boosting” agent to increase blood levels and allow once-daily dosing for certain medicines, including the company’s elvitegravir. The study is designed to evaluate the safety...